Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

ENDRA Life Sciences (NDRA) Cost of Revenue (2016 - 2025)

ENDRA Life Sciences has reported Cost of Revenue over the past 6 years, most recently at $382113.0 for Q4 2021.

  • Quarterly Cost of Revenue rose 98.58% to $382113.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2021, up 84.81% year-over-year, with the annual reading at $189470.0 for FY2025, 66.82% down from the prior year.
  • Cost of Revenue was $382113.0 for Q4 2021 at ENDRA Life Sciences, up from $275565.0 in the prior quarter.
  • Over five years, Cost of Revenue peaked at $382113.0 in Q4 2021 and troughed at -$245364.0 in Q4 2019.
  • The 5-year median for Cost of Revenue is $118270.0 (2017), against an average of $120546.6.
  • Year-over-year, Cost of Revenue surged 8413.48% in 2018 and then plummeted 193.42% in 2019.
  • A 5-year view of Cost of Revenue shows it stood at $3085.0 in 2017, then surged by 8413.48% to $262641.0 in 2018, then plummeted by 193.42% to -$245364.0 in 2019, then surged by 178.42% to $192424.0 in 2020, then soared by 98.58% to $382113.0 in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Cost of Revenue are $382113.0 (Q4 2021), $275565.0 (Q3 2021), and $256763.0 (Q2 2021).